Telomeres and Telomerase: From Discovery to Clinical Trials

David R. Corey

doi:10.1016/j.chembiol.2009.12.001

Telomeres and Telomerase: From Discovery to Clinical Trials

David R. Corey

Research output: Contribution to journal › Comment/debate › peer-review

46 Scopus citations

Abstract

Telomeres are the ends of linear chromosomes. They cannot be fully replicated by standard polymerases and are maintained by the ribonucleoprotein telomerase. Telomeres and telomerase stand at a junction of critical processes underlying chromosome integrity, cancer, and aging, and their importance was recognized by the 2009 Nobel Prize in Physiology or Medicine to Elizabeth Blackburn, Jack Szostak, and Carol Greider. Where will the field go now? What are the prospects for antitelomerase agents as drugs? Nearly 30 years after Szostak and Blackburn's pioneering manuscript on telomere ends, the challenges of discovery remain.

Original language	English (US)
Pages (from-to)	1219-1223
Number of pages	5
Journal	Chemistry and Biology
Volume	16
Issue number	12
DOIs	https://doi.org/10.1016/j.chembiol.2009.12.001
State	Published - Dec 24 2009

Keywords

CELLBIO
CHEMBIO

ASJC Scopus subject areas

Biochemistry
Molecular Medicine
Molecular Biology
Pharmacology
Drug Discovery
Clinical Biochemistry

Access to Document

10.1016/j.chembiol.2009.12.001

Cite this

@article{eaa80219557547da875aad1688246c0c,

title = "Telomeres and Telomerase: From Discovery to Clinical Trials",

abstract = "Telomeres are the ends of linear chromosomes. They cannot be fully replicated by standard polymerases and are maintained by the ribonucleoprotein telomerase. Telomeres and telomerase stand at a junction of critical processes underlying chromosome integrity, cancer, and aging, and their importance was recognized by the 2009 Nobel Prize in Physiology or Medicine to Elizabeth Blackburn, Jack Szostak, and Carol Greider. Where will the field go now? What are the prospects for antitelomerase agents as drugs? Nearly 30 years after Szostak and Blackburn's pioneering manuscript on telomere ends, the challenges of discovery remain.",

keywords = "CELLBIO, CHEMBIO",

author = "Corey, {David R.}",

note = "Funding Information: This work was supported by the National Institutes of Health (NIGMS 73042) and the Robert A. Welch Foundation (I-1244).",

year = "2009",

month = dec,

day = "24",

doi = "10.1016/j.chembiol.2009.12.001",

language = "English (US)",

volume = "16",

pages = "1219--1223",

journal = "Chemistry and Biology",

issn = "1074-5521",

publisher = "Elsevier Inc.",

number = "12",

}

TY - JOUR

T1 - Telomeres and Telomerase

T2 - From Discovery to Clinical Trials

AU - Corey, David R.

N1 - Funding Information: This work was supported by the National Institutes of Health (NIGMS 73042) and the Robert A. Welch Foundation (I-1244).

PY - 2009/12/24

Y1 - 2009/12/24

N2 - Telomeres are the ends of linear chromosomes. They cannot be fully replicated by standard polymerases and are maintained by the ribonucleoprotein telomerase. Telomeres and telomerase stand at a junction of critical processes underlying chromosome integrity, cancer, and aging, and their importance was recognized by the 2009 Nobel Prize in Physiology or Medicine to Elizabeth Blackburn, Jack Szostak, and Carol Greider. Where will the field go now? What are the prospects for antitelomerase agents as drugs? Nearly 30 years after Szostak and Blackburn's pioneering manuscript on telomere ends, the challenges of discovery remain.

AB - Telomeres are the ends of linear chromosomes. They cannot be fully replicated by standard polymerases and are maintained by the ribonucleoprotein telomerase. Telomeres and telomerase stand at a junction of critical processes underlying chromosome integrity, cancer, and aging, and their importance was recognized by the 2009 Nobel Prize in Physiology or Medicine to Elizabeth Blackburn, Jack Szostak, and Carol Greider. Where will the field go now? What are the prospects for antitelomerase agents as drugs? Nearly 30 years after Szostak and Blackburn's pioneering manuscript on telomere ends, the challenges of discovery remain.

KW - CELLBIO

KW - CHEMBIO

UR - http://www.scopus.com/inward/record.url?scp=73149092074&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73149092074&partnerID=8YFLogxK

U2 - 10.1016/j.chembiol.2009.12.001

DO - 10.1016/j.chembiol.2009.12.001

M3 - Comment/debate

C2 - 20064431

AN - SCOPUS:73149092074

SN - 1074-5521

VL - 16

SP - 1219

EP - 1223

JO - Chemistry and Biology

JF - Chemistry and Biology

IS - 12

ER -

Telomeres and Telomerase: From Discovery to Clinical Trials

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this